Image pharmaphorum Editor News US government may cease prescription rebates Pfizer’s CEO believes the US government will eliminate rebates on prescription drugs. News Pioneering Crohn’s antibiotic treatment meets early target A drug targeted at treating Crohn’s disease has shown promise following positive results in a phase 3 trial. Cancer Accord’s biosimilar Pelgraz poised for approval Cancer biosimilar drug Pelgraz is poised to hit the market after receiving a positive opinion by the Committee for Medicinal Products for Human Use (CHMP). Cancer FDA approves first drug to treat rare adrenal cancer Azedra has received FDA approval to become the first and only treatment for a type of rare adrenal cancer. Load more results
News US government may cease prescription rebates Pfizer’s CEO believes the US government will eliminate rebates on prescription drugs.
News Pioneering Crohn’s antibiotic treatment meets early target A drug targeted at treating Crohn’s disease has shown promise following positive results in a phase 3 trial.
Cancer Accord’s biosimilar Pelgraz poised for approval Cancer biosimilar drug Pelgraz is poised to hit the market after receiving a positive opinion by the Committee for Medicinal Products for Human Use (CHMP).
Cancer FDA approves first drug to treat rare adrenal cancer Azedra has received FDA approval to become the first and only treatment for a type of rare adrenal cancer.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.